ULTRAGENYX PHARMACEUTICAL INC. Payments to Acquire Investments
ULTRAGENYX PHARMACEUTICAL INC. (RARE) reported Payments to Acquire Investments of $129.30 million for the 6-month period ending 2014-06-30, per its 10-Q filed 2014-08-11.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireInvestments · last filed 2014-08-11
- ULTRAGENYX PHARMACEUTICAL INC. payments to acquire investments for the quarter ending 2014-06-30 was $41.30M, a 3.98% decline year-over-year.
- ULTRAGENYX PHARMACEUTICAL INC. payments to acquire investments for the quarter ending 2014-03-31 was $88.00M, a 489.68% increase year-over-year.
- ULTRAGENYX PHARMACEUTICAL INC. payments to acquire investments for the quarter ending 2013-06-30 was $43.01M.
- ULTRAGENYX PHARMACEUTICAL INC. payments to acquire investments for the quarter ending 2013-03-31 was $14.92M.
| Period end | Payments to Acquire Investments 3 month | Payments to Acquire Investments 6 month | Payments to Acquire Investments 47 month |
|---|---|---|---|
| 2014-06-30 | $41.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-11 | $129.30M 10-Q · filed 2014-08-11 | |
| 2014-03-31 | $88.00M 10-Q · filed 2014-05-12 | $151.95M 10-Q · filed 2014-05-12 | |
| 2013-06-30 | $43.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-11 | $57.94M 10-Q · filed 2014-08-11 | |
| 2013-03-31 | $14.92M 10-Q · filed 2014-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |